BidaskClub upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a strong sell rating to a sell rating in a research report sent to investors on Wednesday.
Several other research firms have also recently weighed in on RVNC. ValuEngine cut shares of Revance Therapeutics from a hold rating to a sell rating in a research note on Monday, December 4th. Cowen set a $55.00 target price on shares of Revance Therapeutics and gave the company a buy rating in a research note on Wednesday, January 17th. Piper Jaffray Companies increased their target price on shares of Revance Therapeutics from $28.00 to $51.00 and gave the company an overweight rating in a research note on Tuesday, December 5th. Mizuho reiterated a buy rating and issued a $54.00 target price on shares of Revance Therapeutics in a research note on Friday, January 5th. Finally, Guggenheim reiterated a neutral rating and issued a $42.00 target price on shares of Revance Therapeutics in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $44.30.
Revance Therapeutics (NASDAQ RVNC) traded up $0.90 during midday trading on Wednesday, hitting $31.65. 183,300 shares of the company traded hands, compared to its average volume of 314,229. Revance Therapeutics has a twelve month low of $18.00 and a twelve month high of $37.45. The company has a market capitalization of $1,160.00, a PE ratio of -8.37 and a beta of 1.36.
In related news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total value of $189,544.00. Following the completion of the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 18.86% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Cowen Inc. acquired a new position in Revance Therapeutics in the fourth quarter worth about $225,000. Jane Street Group LLC acquired a new position in Revance Therapeutics in the fourth quarter worth about $685,000. 1492 Capital Management LLC acquired a new position in Revance Therapeutics in the fourth quarter worth about $1,393,000. TIAA CREF Investment Management LLC raised its position in Revance Therapeutics by 4.6% in the fourth quarter. TIAA CREF Investment Management LLC now owns 62,863 shares of the biopharmaceutical company’s stock worth $2,247,000 after purchasing an additional 2,759 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in Revance Therapeutics by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 42,535 shares of the biopharmaceutical company’s stock worth $1,521,000 after purchasing an additional 1,620 shares in the last quarter. 77.84% of the stock is owned by hedge funds and other institutional investors.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.